---
layout: post
title: "康希诺：该公司的mRNA疫苗媲美辉瑞莫德纳"
date: 2023-02-04T02:49:52.282Z
author: 联合早报
from: https://www.zaobao.com/realtime/china/story20230204-1359600
tags: [ 联合早报 ]
comments: True
categories: [ 联合早报 ]
---
<!--NaN-->
[康希诺：该公司的mRNA疫苗媲美辉瑞莫德纳](https://www.zaobao.com/realtime/china/story20230204-1359600)
------

<div>
<p>中国制药商<span><span><span><span><span><span><span>康希诺生物首席执行官</span></span></span></span></span></span></span><span><span><span><span><span><span><span>宇学峰</span></span></span></span></span></span></span><span><span><span><span><span><span><span>表示，该公司使用</span></span></span></span></span></span></span><span><span><span><span><span><span><span>信使核糖核酸（mRNA）</span></span></span></span></span></span></span><span><span><span><span><span><span><span>技术的实验性冠病疫苗可以媲美</span></span></span></span></span></span></span><span><span><span><span><span><span><span>莫德纳（Moderna）</span></span></span></span></span></span></span><span><span><span><span><span><span><span>和</span></span></span></span></span></span></span><span><span><span><span><span><span><span>辉瑞-</span></span></span></span></span></span></span><span><span><span><span><span><span><span>BioNTech（</span></span></span></span></span></span></span><span><span><span><span><span><span><span>Pfizer-BioNTech）的疫苗。</span></span></span></span></span></span></span></p><p><span><span><span><span><span><span><span>据路透社报道，</span></span></span></span></span></span></span><span><span><span><span><span><span><span>宇学峰</span></span></span></span></span></span></span><span><span><span><span><span><span><span>星期五（2月3日）</span></span></span></span></span></span></span><span><span><span><span><span><span><span>称</span></span></span></span></span></span></span><span><span><span><span><span><span><span>，由于</span></span></span></span></span></span></span><span><span><span><span><span><span><span>莫德纳和</span></span></span></span></span></span></span><span><span><span><span><span><span><span>辉瑞-</span></span></span></span></span></span></span><span><span><span><span><span><span><span>BioNTech</span></span></span></span></span></span></span><span><span><span><span><span><span><span>疫苗在中国国内没有被批准使用，因此无法与对</span></span></span></span></span></span></span><span><span><span><span><span><span><span>康希诺</span></span></span></span></span></span></span><span><span><span><span><span><span><span>疫苗进行直接比较研究，但是根据已公布的数据，他相信</span></span></span></span></span></span></span><span><span><span><span><span><span><span>康希诺</span></span></span></span></span></span></span><span><span><span><span><span><span><span>的产品和已经上市的mRNA疫苗一样好。</span></span></span></span></span></span></span></p><p><span><span><span><span><span><span><span>康希诺1月5日发布公告称，首款mRNA疫苗CS-2034已进入试生产阶段，并且在一项评估序贯加强安全性和免疫原性的临床研究中，取得了积极的阶段性数据。</span></span></span></span></span></span></span></p><section id="imu"><div id="dfp-ad-imu1">        </div></section><p><span><span><span><span><span><span><span>针对中国政府是否有较强意愿研发国产mRNA疫苗的问题，</span></span></span></span></span></span></span><span><span><span><span><span><span><span>宇学峰</span></span></span></span></span></span></span><span><span><span><span><span><span><span>说，目前没有太多关于这方面的公开信息，但从技术的角度来看，任何产品只要符合监管要求，就没有理由不让它们进入市场。</span></span></span></span></span></span></span></p><p><span><span><span><span><span><span><span>宇学峰</span></span></span></span></span></span></span><span><span><span><span><span><span><span>说，</span></span></span></span></span></span></span><span><span><span><span><span><span><span>康希诺</span></span></span></span></span></span></span><span><span><span><span><span><span><span>目前正在与中国监管机构就CS-2034的后期研究方案进行讨论，将在今年进行试验。</span></span></span></span></span></span></span></p><p><span><span><span><span><span><span><span>他也说，如果疫苗获得批准，该公司将想办法降低制造和部署mRNA疫苗的成本。</span></span></span></span></span></span></span></p><div id="innity-in-post"></div><div id="dfp-ad-midarticlespecial">        </div><p><span><span><span><span><span><span><span>他指出，与辉瑞今年希望在美国售卖每剂约120美元（约158.83新元）的疫苗相比，</span></span></span></span></span></span></span><span><span><span><span><span><span><span>康希诺的</span></span></span></span></span></span></span><span><span><span><span><span><span><span>疫苗肯定会更便宜。</span></span></span></span></span></span></span></p><p><span><span><span><span><span><span><span>中国在去年12月放松冠病防疫限制后，迄今为止尚未批准使用国外的mRNA疫苗，也未批准使用该技术的国产疫苗。</span></span></span></span></span></span></span></p><p><span><span><span><span><span><span><span>据了解，mRNA技术与传统疫苗方法相比更具可塑性，也更容易调整以解决新的变体，但mRNA疫苗通常需要更昂贵的超级冷库储存。目前研究人员在确保疫苗在较高温度下保持稳定方面取得了一些进展。</span></span></span></span></span></span></span></p>      <div class="cx_paywall_placeholder" id="sph_cdp_40"></div>
</div>
